Across the recent three months, 4 analysts have shared their insights on VYNE Therapeutics (NASDAQ:VYNE), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
0
0
0
0
Last 30D
1
0
0
0
0
1M Ago
1
0
0
0
0
2M Ago
2
0
0
0
0
3M Ago
0
0
0
0
0
Insights from analysts' 12-month price targets are revealed, presenting an average target of $5.75, a high estimate of $5.75, and a low estimate of $5.75. Holding firm without variation, the current average remains at the previous average price target.
Decoding Analyst Ratings: A Detailed Look
In examining recent analyst actions, we gain insights into how financial experts perceive VYNE Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Joseph Pantginis
HC Wainwright & Co.
Maintains
Buy
$5.75
$5.75
Joseph Pantginis
HC Wainwright & Co.
Maintains
Buy
$5.75
$5.75
Joseph Pantginis
HC Wainwright & Co.
Maintains
Buy
$5.75
$5.75
Joseph Pantginis
HC Wainwright & Co.
Maintains
Buy
$5.75
$5.75
Key Insights:
Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to VYNE Therapeutics. This information offers a snapshot of how analysts perceive ...Full story available on Benzinga.com
Benzinga
